Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Computational modeling reveals MAP3K8 as mediator of resistance to vemurafenib in thyroid cancer stem cells

26 Nov 2018

Abstract excerpt

MOTIVATION: Val600Glu (V600E) mutation is the most common BRAF mutation detected in thyroid cancer. Hence, recent research efforts have been performed trying to explore several inhibitors of the V600E mutation-containing BRAF kinase as potential therapeutic options in thyroid cancer refractory to standard interventions. Among them, vemurafenib is a selective BRAF inhibitor approved by Food and Drug Administration...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fibroblast Growth Factor Research
Share to Melanoma and MAPK Pathways
Share to Thyroid Cancer Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30481266
DOI: 10.1093/bioinformatics/bty969

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Computational modeling reveals MAP3K8 as mediator of resistance to vemurafenib in thyroid cancer stem cellsPMID 30481266Read ↗

Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.Semantic proximity Read ↗

Inhibition of MEK Signaling Attenuates Cancer Stem Cell Activity in Anaplastic Thyroid Cancer.Semantic proximity Read ↗

Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.Semantic proximity Read ↗

Anaplastic thyroid cancer spheroids as preclinical models to test therapeuticsSemantic proximity Read ↗

Human menstrual blood-derived stem cells reverse sorafenib resistance in hepatocellular carcinoma cells through the hyperactivation of mitophagySemantic proximity Read ↗

Multicellular spheroids from normal and neoplastic thyroid tissues as a suitable model to test the effects of multikinase inhibitors.Semantic proximity Read ↗

Utilizing CD44v6 and V600EBRAF-mutation for in vitro targeted combination therapy of thyroid carcinomasSemantic proximity Read ↗

Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid CancerSemantic proximity Read ↗

Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma.Semantic proximity Read ↗

[Molecular mechanism of thyroid carcinogenesis].Semantic proximity Read ↗

Targeting PEAK1 sensitizes anaplastic thyroid carcinoma cells harboring BRAFV600E to Vemurafenib by Bim upregulation.Semantic proximity Read ↗

BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.